Strand Displacement Amplification Market

Strand Displacement Amplification Market Analysis

The Strand Displacement Amplification Market is expected to register a CAGR of 5.2% during the forecast period.

• The impact of COVID-19 on the studied market was significant as several strand displacement amplification-based products were developed to detect COVID-19. For instance, according to the study published in Nature Communications in August 2021, a non-enzymatic isothermal strand displacement and amplification (NISDA) was developed to detect SARS-CoV-2 RNA.
• A study was conducted to test its efficacy, and it was seen that in 164 clinical oropharyngeal RNA samples, the NISDA assay was 100 % specific, and it was 96.77% and 100% sensitive when used in the laboratory and hospital, respectively. Thus, the COVID-19 pandemic impacted the market significantly, as strand displacement amplification tests were developed to detect COVID-19. However, as the pandemic subsided, the studied market is expected to have normal growth during the forecast period of the study.
• Factors that are driving the market growth include increasing prevalence and incidence of infectious diseases such as tuberculosis and hepatitis, among others. Other factors that are driving the market growth include the rising prevalence of chronic diseases and the growing adoption of point-of-care testing.
• The rising prevalence of chronic and infectious diseases around the world is one of the major factors driving the market growth, as it will lead to the usage of more strand displacement amplification tests. For instance, according to the data published by the World Health Organization (WHO) in September 2022, a total of 348.9 thousand specimens were processed in China for influenza testing, out of which 49,260 cases were found to be positive. The source also stated that 211.6 thousand specimens were tested in Australia for influenza, out of which 11,311 cases turned out to be positive. Thus, the high prevalence of such infectious diseases is expected to boost the adoption of strand displacement amplification tests.
• Moreover, according to an article published by the WHO in 2022, an estimated 10.6 million around the world people fell ill with tuberculosis in 2021, which showed an increase of 4.5% from 10.1 million in the previous year. The source also stated that China accounted for 7.4% of tuberculosis cases around the world in 2021, which is the third highest.
• China is also considered a high-burden country for tuberculosis (TB), Human Immunodeficiency Virus (HIV) related TB, and Multidrug-resistant tuberculosis /rifampicin-resistant (MDR/RR-TB) from 2021 to 2025. Thus, the high prevalence of tuberculosis around the world is also expected to boost market growth.
• Additionally, the increasing demand for point-of-care testing is also expected to boost market growth, as it will lead to the increased usage of strand displacement amplification products. For instance, according to an article published by PubMed in March 2022, point-of-care testing (POCT) has been gaining attention as a tool that can provide immediate test results, and its adoption is increasing around the world.
• Hence, the factors above, such as the rising prevalence of chronic and infectious diseases and the growing adoption of point-of-care testing, are expected to enhance market growth. However, the disadvantages associated with the procedure and the availability of alternative procedures are expected to hinder market growth.

Strand Displacement Amplification Market Trends

Cancer Segment is Expected to Hold Significant Market Share Over the Forecast Period

• Cancer is a disease in which some of the body's cells grow uncontrollably and spread to other body parts. It is a significant disease with a very high burden around the world. The rising prevalence of cancer is the major factor driving the market growth.
• The high prevalence of cancer worldwide is one of the major factors driving the segment's growth. For instance, as per the report published by PubMed Central in March 2022, China is experiencing a greater incidence of cancers. In 2022 it was expected that there would be approximately 4,820,000 new cancer cases in China; lung cancer is the most common. Thus, the high prevalence of cancer in the country is expected to boost segment growth.
• Furthermore, according to an article published by Cancer Research and Treatment in March 2022, it was estimated that 28,142 new breast cancer cases were noted in South Korea in 2022, out of which 28,032 were female and 110 were male. The source also stated that the age-standardized incidence of breast cancer in South Korea was 33.1 out of 100,000 in 2022. Thus, the high burden of cancer in South Korea is expected to boost the segment's growth.
• Moreover, according to an article published by Chemical Communications in 2021, microRNA-21 (miR-21) is considered a potential biomarker for cancer diagnosis and prognosis due to its high expression in tumors, and a multiple cascaded strand displacement amplification method was developed to detect it effectively. Additionally, according to an article published by ScienceDirect in 2023, a stepwise strand displacement amplification (S-SDA) based colorimetric sensing platform was developed, which was found useful in clinical settings for the detection of colon cancer.
• Hence, the factors above, such as the rising prevalence of cancer and the increasing usage of strand displacement amplification in cancer biomarker identification, are expected to boost the studied segment's growth.

North America is Expected to Hold a Significant Market Share Over the Forecast Period

• North America is anticipated to hold a significant market share over the forecast period owing to the increasing prevalence of chronic diseases, the rising geriatric population, and the presence of key market players in the region.
• The rising prevalence of chronic diseases in the region is one of the major factors driving the market growth. For instance, according to the data updated by the Center for Disease Control and Prevention (CDC) in January 2022, an estimated 91 pediatric flu deaths have been reported so far in the 2022-23 season in the United States. The source also estimates that, so far this season, there have been approximately 25 million illnesses, 280,000 hospitalizations, and 17,000 deaths from flu.
• Moreover, the rising prevalence of infectious diseases, such as HIV, RSV, and hepatitis C, is also expected to boost the demand for lateral flow assays to detect these diseases. For instance, according to the data updated by the CDC in 2022, it was estimated that in the 2022-2023 season, the overall rate of RSV-associated hospitalizations was 43.4 per 100,000 people.
• Additionally, according to the data stated by the Canadian Cancer Society in November 2022, it was estimated that 233,900 people were diagnosed with cancer in 2022. This incidence growth is mainly due to Canada's growing aging population. Thus, the growing prevalence of cancer is expected to boost the usage of strand displacement amplification tests, thus driving the growth of the market in the region over the forecast period.

Strand Displacement Amplification Industry Overview

The strand displacement amplification market is moderately competitive and consists of several players. Some key players in the strand displacement amplification market are Bio-Rad Laboratories, Inc., G Biosciences, Hopax Fine Chemicals, Lucigen, New England Biolabs, and Nippon Genetics. Co. Ltd, among others.

Strand Displacement Amplification Market Leaders

Strand Displacement Amplification Market News

• February 2023: Sherlock Biosciences acquired Sense Biodetection to reach its goal of making diagnostics easy to use, cheap, disposable, and good for the environment. Sense Biodetection provides SDA-based diagnostic products.
• January 2023: Lucira Health, Inc. submitted an Emergency Use Authorization application to the FDA for OTC use of its simple, at-home molecular COVID-19 & Flu test, which uses SDA technology.